FindTrial
Sign In

Placebo to Denosumab

DRUG4 trials

Sponsors

Amgen

Conditions

Bone MetastasesCancerHematologic MalignanciesLow Bone Mineral DensityMultiple MyelomaMultiple Myeloma Bone LesionsNon-Small Cell Lung CancerOncology

Phase 2

Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density
CompletedNCT00896532
AmgenLow Bone Mineral Density, Postmenopausal Osteoporosis
Start: 2009-06-03End: 2016-02-18Updated: 2022-09-22
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
CompletedNCT01951586
AmgenNon-Small Cell Lung Cancer
Start: 2013-12-31End: 2017-11-28Updated: 2021-10-25

Phase 3

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
CompletedNCT01345019
AmgenBone Metastases, Cancer, Hematologic Malignancies +3
Start: 2012-05-17End: 2019-03-29Updated: 2022-11-08

Phase 4

Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis
CompletedNCT01732770
AmgenPost Menopausal Osteoporosis
Start: 2012-11-07End: 2015-01-07Updated: 2020-03-10

Related Papers

Romosozumab significantly improves vertebral cortical bone mass and structure compared with teriparatide, whereas both treatments increase vertebral trabecular bone mass similarly: high-resolution quantitative computed tomography analyses of randomized controlled trial results in postmenopausal women with low bone mineral density
JBMR Plus2025-07-151 citations
Response rates for lumbar spine, total hip, and femoral neck bone mineral density in men treated with abaloparatide: results from the ATOM study
JBMR Plus2024-01-274 citations
Skeletal responses to romosozumab after 12 months of denosumab
JBMR Plus2021-05-1469 citations
Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study
Blood Advances2021-02-0241 citations
Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study-Asian Subgroup Analysis.
2020-06-1011 citations
Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates.
2019-11-2844 citations
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study
Journal of Bone and Mineral Research2018-04-25223 citations
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
2018-02-09302 citations
Impact of denosumab (DMB) compared with zoledronic acid (ZA) on renal function in the treatment of myeloma bone disease.
Journal of Clinical Oncology2017-05-2012 citations
Denosumab compared with zoledronic acid for the treatment of bone disease in adults with newly diagnosed multiple myeloma: An international, randomized, double-blind trial.
Journal of Clinical Oncology2015-05-20
A randomized, double-blind, multinational trial comparing denosumab with zoledronic acid for treatment of bone disease in adults with newly diagnosed multiple myeloma.
Journal of Clinical Oncology2014-05-201 citations
A randomized, double-blind, multicenter phase 2 trial of denosumab in combination with chemotherapy as first-line treatment of metastatic non-small cell lung cancer.
Journal of Clinical Oncology2014-05-201 citations
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
New England Journal of Medicine2014-01-011203 citations